CONSHOHOCKEN, PA — AdaptHealth Corp. (NASDAQ: AHCO) announced it recently completed the sale of certain infusion assets from its Wellness at Home segment to a third party earlier this month, continuing its strategy to streamline operations and focus on core business lines.
The divested assets generated approximately $52 million in annual revenue and $5 million in annual adjusted EBITDA. The sale aligns with AdaptHealth’s plan to exit ancillary product lines and focus resources on areas with stronger strategic fit.
“The disposition of certain infusion assets marks yet another significant step in our effort to sharpen our strategic focus by exiting ancillary product lines,” said Suzanne Foster, CEO of AdaptHealth. “Additionally, the sale advances our commitment to debt reduction to unlock value for our shareholders.”
Proceeds from the sale, combined with other funds, were used to make a $65 million prepayment on the company’s outstanding term loan. This follows a $70 million prepayment in May, funded primarily by the sale of incontinence assets.
In conjunction with the transaction, AdaptHealth revised its 2025 financial guidance. The company now expects full-year revenue between $3.15 billion and $3.29 billion, adjusted EBITDA ranging from $662 million to $702 million, and free cash flow between $170 million and $190 million. The company also anticipates approximately $30 million in cash taxes tied to gains from the infusion asset sale.
The move underscores AdaptHealth’s commitment to strengthening its balance sheet while concentrating on its core home healthcare offerings, positioning the company for more focused growth in the coming years.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.